Suppr超能文献

接受质子束治疗前列腺癌患者的胃肠道毒性分析:单机构经验

Analysis of Gastrointestinal Toxicity in Patients Receiving Proton Beam Therapy for Prostate Cancer: A Single-Institution Experience.

作者信息

Lee Howard J, Macomber Meghan W, Spraker Matthew B, Bowen Stephen R, Hippe Daniel, Fung Angela, Russell Kenneth J, Laramore George E, Rengan Ramesh, Liao Jay, Apisarnthanarax Smith, Zeng Jing

机构信息

Duke University School of Medicine, Durham, North Carolina.

Department of Radiation Oncology, University of Washington School of Medicine, Seattle, Washington.

出版信息

Adv Radiat Oncol. 2018 Aug 13;4(1):70-78. doi: 10.1016/j.adro.2018.08.002. eCollection 2019 Jan-Mar.

Abstract

PURPOSE

We characterized both physician- and patient-reported rates of gastrointestinal (GI) toxicity in patients treated with proton beam therapy (PBT) at our institution for prostate adenocarcinoma and identified factors associated with toxicity.

METHODS AND MATERIALS

We treated 192 patients with PBT between July 2013 and July 2016. Included patients had ≥1 year of follow-up. Potential preexisting clinical and treatment-related risk factors for GI toxicity were recorded. Common Terminology Criteria for Adverse Events version 4.0 was used to score toxicity. Expanded Prostate Cancer Index Composite (EPIC) bowel domain questionnaires assessed patient-reported quality of life. Associations between grade (GR) 2+ toxicity and clinical, treatment, and dosimetric factors were assessed using Cox models and corresponding hazard ratios.

RESULTS

The median follow-up was 1.7 years. Most of the observed GI toxicity (>90%) was in the form of rectal bleeding (RB). GR2+ GI toxicity and RB actuarial rates specifically at 2 years were 21.3% and 20.4%, respectively. GR3 toxicity was rare, with only 1 observed RB event. No GR4/5 toxicity was seen. The EPIC bowel domain median score was 96 (range, 61-100) pretreatment, 93 (range, 41-100) at 1 year, 89 (range, 57-100) at 1.5 years, and 89 (range, 50-100) at 2 years. Anticoagulation use was the only factor selected during multivariate analysis for predicting GR2+ RB, with a resulting concordance index of 0.59 (95% confidence interval, 0.48-0.68; = .088). Type of proton technology (pencil beam scanning vs uniform scanning) and number of fields treated per day (1 vs 2) showed no significant difference in toxicity rate.

CONCLUSIONS

PBT was associated with acceptable rates of GR2+ transient GI toxicity, mostly in the form of RB, which correlated with anticoagulation use. High EPIC bowel domain quality of life was maintained in the 2 years after treatment.

摘要

目的

我们对在本机构接受质子束治疗(PBT)的前列腺腺癌患者中医生报告和患者报告的胃肠道(GI)毒性发生率进行了特征描述,并确定了与毒性相关的因素。

方法和材料

2013年7月至2016年7月期间,我们对192例患者进行了PBT治疗。纳入的患者有≥1年的随访。记录了潜在的既往临床和治疗相关的GI毒性风险因素。使用不良事件通用术语标准第4.0版对毒性进行评分。扩展前列腺癌指数综合(EPIC)肠道领域问卷评估患者报告的生活质量。使用Cox模型和相应的风险比评估2级及以上(GR2+)毒性与临床、治疗和剂量学因素之间的关联。

结果

中位随访时间为1.7年。观察到的大多数GI毒性(>90%)表现为直肠出血(RB)。GR2+ GI毒性和RB的2年精算发生率分别为21.3%和20.4%。GR3毒性罕见,仅观察到1例RB事件。未观察到GR4/5毒性。EPIC肠道领域的中位评分在治疗前为96(范围61 - 100),1年时为93(范围41 - 100),1.5年时为89(范围57 - 100),2年时为89(范围50 - 100)。在多变量分析中,抗凝药物的使用是预测GR2+ RB的唯一因素,一致性指数为0.59(95%置信区间,0.48 - 0.68;P = 0.088)。质子技术类型(笔形束扫描与均匀扫描)和每天治疗的射野数(1个与2个)在毒性发生率上无显著差异。

结论

PBT与可接受的GR2+短暂GI毒性发生率相关,主要表现为RB,这与抗凝药物的使用相关。治疗后2年内维持了较高的EPIC肠道领域生活质量。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b01/6349581/f3b07d07374f/gr1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验